Answers are grounded in this paper and cite their sources.
The Swiss drug contract development and manufacturing organization (CDMO) Lonza has named Siegfried Holding's CEO Wolfgang Wienand as its new chief executive, effective this summer. Wienand will replace Lonza's interim CEO, Albert M. Baehny, who has been in the role since October. Wienand has been with Siegfried since 2010, where he held the roles of chief scientific officer and strategy officer before being promoted to CEO in 2019. Before Siegfried, Wienand, who has a PhD in chemistry from the University of Cologne, held senior positions at the German chemical company Evonik Industries. Lonza has had trouble keeping executives at the helm. In 2019, the company announced the sudden retirement of its then-CEO, Richard Ridinger. He was succeeded by a company executive, Marc Funk, who lasted just nine months as CEO. In 2020, Lonza named Pierre-Alain Ruffieux CEO. He left the organization after serving for three years, after which Baehny, then
No takes yet. Share an insight, caveat, or question.
Aayushi Pratap (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: